Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory study of teriflunomide effects on blood immune cell subsets in relapsing multiple sclerosis
NL-OMON40257Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in lymphocyte subset parameters. Started Oct 2013; status: active, not recruiting.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON40257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40257.